Oncopeptides ABFRA:OND +0.35%28 Return-on-Tangible-Equity is -1,392.20% as of Mar. 2026. GuruFocus rates FRA:OND with a GF Score™ of 28/100 and a GF Value™ of €0.37 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,196 Biotechnology companies, Oncopeptides AB ranks worse than 83611.96% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Oncopeptides AB's annualized net income for the quarter that ended in Mar. 2026 was €-11.95 Mil. Oncopeptides AB's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €0.86 Mil. Therefore, Oncopeptides AB's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -1,392.20%.
The historical rank and industry rank for Oncopeptides AB's Return-on-Tangible-Equity or its related term are showing as below:
FRA:OND's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -42.19 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Oncopeptides AB (FRA:OND) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Oncopeptides AB Return-on-Tangible-Equity Related Terms
Oncopeptides AB Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Oncopeptides AB's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:OND vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Oncopeptides AB's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncopeptides AB Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncopeptides AB's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Oncopeptides AB's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -1,392.20% mean?
Oncopeptides AB (FRA:OND) has a Return-on-Tangible-Equity of -1,392.20% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Oncopeptides AB and its competitors. According to the industry distribution chart, Oncopeptides AB ranks #999999 out of 1196 companies in the Biotechnology industry.
Is Oncopeptides AB's Return-on-Tangible-Equity too high?
Oncopeptides AB's current Return-on-Tangible-Equity is -1,392.20%. Based on the distribution chart, Oncopeptides AB ranks #999999 out of 1196 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oncopeptides AB has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncopeptides AB's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncopeptides AB ranks #999999 out of 1196 companies for Return-on-Tangible-Equity. This places Oncopeptides AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Oncopeptides AB and its competitors. Oncopeptides AB's current Return-on-Tangible-Equity is -1,392.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncopeptides AB stock overvalued right now?
Based on GuruFocus' analysis, Oncopeptides AB (FRA:OND) is currently considered Possible Value Trap. The stock's GF Value™ is €0.37, compared to a current price of €0.15 — trading 60.7% below its estimated fair value. The current Return-on-Tangible-Equity is -1,392.20%. Oncopeptides AB's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Oncopeptides AB (FRA:OND), the current Return-on-Tangible-Equity is -1,392.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncopeptides AB (FRA:OND) Overvalued in 2026?
Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued.
The current stock price of €0.15 is trading 60.7% below its estimated GF Value™ of €0.37.
GuruFocus considers Oncopeptides AB to be Possible Value Trap.
Key valuation signals for FRA:OND:
Return-on-Tangible-Equity: -1,392.20%
GF Value™: €0.37 vs. price of €0.15 (60.7% below fair value)
No single metric tells the full story. See the FRA:OND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
28GF Score
Get the complete analysis for FRA:OND
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OND has been successfully added to your 
